Capstone Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.74M | Buy |
3,895
+656
| +20% | +$306K | ﹤0.01% | 684 |
|
|
2025
Q4 | $1.47M | Sell |
3,239
-2,784
| -46% | -$1.2M | ﹤0.01% | 717 |
|
|
2025
Q3 | $2.36M | Buy |
6,023
+3,664
| +155% | +$1.53M | ﹤0.01% | 714 |
|
|
2025
Q2 | $1.05M | Buy |
+2,359
| New | +$1.09M | ﹤0.01% | 838 |
|
|
2025
Q1 | – | Sell |
-7,980
| Closed | -$3.72M | – | 1905 |
|
|
2024
Q4 | $3.21M | Buy |
7,980
+7,110
| +817% | +$3.3M | 0.01% | 684 |
|
|
2024
Q3 | $405K | Buy |
+870
| New | +$418K | ﹤0.01% | 1278 |
|
|
2024
Q2 | – | Sell |
-4,359
| Closed | -$1.89M | – | 2509 |
|
|
2024
Q1 | $1.82M | Buy |
4,359
+3,013
| +224% | +$1.27M | 0.01% | 823 |
|
|
2023
Q4 | $548K | Buy |
+1,346
| New | +$497K | ﹤0.01% | 1295 |
|
|
2023
Q2 | – | Sell |
-3,063
| Closed | -$1.03M | – | 1915 |
|
|
2023
Q1 | $965K | Buy |
3,063
+2,094
| +216% | +$628K | ﹤0.01% | 806 |
|
|
2022
Q4 | $280K | Buy |
+969
| New | +$295K | ﹤0.01% | 1234 |
|
|
2022
Q3 | – | Sell |
-1,193
| Closed | -$343K | – | 1772 |
|
|
2022
Q2 | $336K | Buy |
1,193
+1,192
| +119,200% | +$319K | ﹤0.01% | 1329 |
|
|
2022
Q1 | $0 | Sell |
1
-12,059
| -100% | -$2.86M | ﹤0.01% | 2165 |
|
|
2021
Q4 | $2.65M | Sell |
12,060
-89,256
| -88% | -$17.4M | ﹤0.01% | 1038 |
|
|
2021
Q3 | $18.4M | Buy |
101,316
+65,894
| +186% | +$12.9M | 0.04% | 435 |
|
|
2021
Q2 | $7.14M | Buy |
35,422
+22,814
| +181% | +$4.77M | 0.02% | 630 |
|
|
2021
Q1 | $2.71M | Sell |
12,608
-19,479
| -61% | -$4.28M | 0.01% | 831 |
|
|
2020
Q4 | $7.58M | Buy |
+32,087
| New | +$7.36M | 0.03% | 470 |
|
|
2019
Q4 | – | Sell |
-158
| Closed | -$32K | – | 1464 |
|
|
2019
Q3 | $27K | Sell |
158
-5,224
| -97% | -$924K | ﹤0.01% | 1315 |
|
|
2019
Q2 | $987K | Sell |
5,382
-565
| -10% | -$98.8K | 0.01% | 952 |
|
|
2019
Q1 | $1.09M | Buy |
5,947
+5,789
| +3,664% | +$1.07M | 0.01% | 783 |
|
|
2018
Q4 | $26K | Sell |
158
-1,744
| -92% | -$302K | ﹤0.01% | 1211 |
|
|
2018
Q3 | $367K | Buy |
+1,902
| New | +$339K | ﹤0.01% | 864 |
|
|
2017
Q4 | – | Sell |
-2,600
| Closed | -$395K | – | 670 |
|
|
2017
Q3 | $395K | Buy |
+2,600
| New | +$391K | 0.01% | 351 |
|
|
2016
Q4 | – | Sell |
-28,284
| Closed | -$2.47M | – | 1123 |
|
|
2016
Q3 | $2.47M | Buy |
+28,284
| New | +$2.67M | 0.05% | 229 |
|
|
2016
Q2 | – | Sell |
-4,600
| Closed | -$365K | – | 860 |
|
|
2016
Q1 | $365K | Buy |
+4,600
| New | +$416K | 0.01% | 466 |
|
Other funds holding VRTX
VCM
VPM
Capstone Investment Advisors's VRTX Position: Q1 2026 in Review
Capstone Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, buying an estimated $306K and bringing the position to 3,895 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #684.
Capstone Investment Advisors first reported a position in VRTX in Q1 2016 and has held it in 25 quarters since. The position peaked at $18.4M in Q3 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Capstone Investment Advisors held 3,895 shares of Vertex Pharmaceuticals worth $1.74M as of Q1 2026.
- Capstone Investment Advisors bought 656 Vertex Pharmaceuticals shares in Q1 2026, an estimated $306K.
- Vertex Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #684 holding.
- Capstone Investment Advisors first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
- Capstone Investment Advisors's Vertex Pharmaceuticals position peaked at $18.4M in Q3 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.